These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics. Zhang J; Wu L; Su T; Liu H; Jiang L; Jiang Y; Wu Z; Chen L; Li H; Zheng J; Sun Y; Peng H; Han R; Ning G; Ye L; Wang W Front Endocrinol (Lausanne); 2024; 15():1365321. PubMed ID: 38779454 [TBL] [Abstract][Full Text] [Related]
6. Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature. El Ghorayeb N; Rondeau G; Latour M; Cohade C; Olney H; Lacroix A; Perrotte P; Sabourin A; Mazzuco TL; Bourdeau I Medicine (Baltimore); 2016 Mar; 95(13):e3180. PubMed ID: 27043680 [TBL] [Abstract][Full Text] [Related]
7. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514 [TBL] [Abstract][Full Text] [Related]
8. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067 [TBL] [Abstract][Full Text] [Related]
9. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma. Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537 [TBL] [Abstract][Full Text] [Related]
10. Update in adrenocortical carcinoma. Fassnacht M; Kroiss M; Allolio B J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734 [TBL] [Abstract][Full Text] [Related]
11. [Features of clinical presentation of malignant adrenocortical tumor cortex metabolism over time]. Kvacheniuk AM Lik Sprava; 2003 Dec; (8):52-4. PubMed ID: 14965007 [TBL] [Abstract][Full Text] [Related]
12. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647 [TBL] [Abstract][Full Text] [Related]
13. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392 [TBL] [Abstract][Full Text] [Related]
14. Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. Reidy-Lagunes DL; Lung B; Untch BR; Raj N; Hrabovsky A; Kelly C; Gerst S; Katz S; Kampel L; Chou J; Gopalan A; Saltz LB Oncologist; 2017 Sep; 22(9):1102-1106. PubMed ID: 28559412 [TBL] [Abstract][Full Text] [Related]
16. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. Megerle F; Herrmann W; Schloetelburg W; Ronchi CL; Pulzer A; Quinkler M; Beuschlein F; Hahner S; Kroiss M; Fassnacht M; J Clin Endocrinol Metab; 2018 Apr; 103(4):1686-1695. PubMed ID: 29452402 [TBL] [Abstract][Full Text] [Related]
17. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation. Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients. Maiter D; Bex M; Vroonen L; T'Sjoen G; Gil T; Banh C; Chadarevian R Ann Endocrinol (Paris); 2016 Oct; 77(5):578-585. PubMed ID: 27063476 [TBL] [Abstract][Full Text] [Related]
19. Current and emerging therapies for adrenocortical carcinoma--review. Przytulska J; Rogala N; Bednarek-Tupikowska G Adv Clin Exp Med; 2015; 24(2):185-93. PubMed ID: 25931348 [TBL] [Abstract][Full Text] [Related]
20. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells. Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]